Abstract:Bit by bit functional genomic tools have been piecing together the molecular puzzle driving tumorigenesis in human patients since the last few decades. Nevertheless, our understanding of the role of several genes and regulatory elements that drive critical cancer-associated physiological processes from disease development to progression to spread is abysmal, which significantly impacts our ability of applying these insights in the context of improved disease management. The recent advent of CRISPR-Cas9-based technology and its application in cancer genomics has however allowed the generation of a wealth of knowledge that has helped decipher several critical questions associated with translational cancer research. Precisely, the high throughput capability coupled with an extreme level of technological plasticity associated with the CRISPR-Cas9 screens have expanded our horizons from merely struggling to appreciate cancer as a genetic disease to observing at the integrated genomic/epigenomic network of numerous malignancies and correlating it with our present knowledge of drugging strategies to develop innovative approaches for next generation cancer precision medicine. Specifically, within blood cancers, current CRISPR screens have specifically focused on improving our understanding of drug resistance strategies, disease biology, development of novel therapeutic approaches, and identifying the molecular mechanisms of current therapies, with an underlying aim of improving disease outcomes. Here, we review the development of CRISPR-Cas9 genome editing strategy, explicitly focusing on the recent advances in the CRISPR-Cas9 based screening approaches, its current capabilities, limitations, and future applications in the context of hematological malignancies.

CRISPR Screens in Mechanism and Target Discovery for AML

Therapeutic Target Discovery Using High-Throughput Genetic Screens in Acute Myeloid Leukemia

CRISPR Screen in Mechanism and Target Discovery for Cancer Immunotherapy

Application of CRISPR screen in mechanistic studies of tumor development, tumor drug resistance, and tumor immunotherapy

Advancements in CRISPR Screens for the Development of Cancer Immunotherapy Strategies

Evolution of Molecular Targeted Cancer Therapy: Mechanisms of Drug Resistance and Novel Opportunities Identified by CRISPR-Cas9 Screening

A CRISPR Dropout Screen Identifies Genetic Vulnerabilities and Therapeutic Targets in Acute Myeloid Leukemia

CRISPR Screens in Synthetic Lethality and Combinatorial Therapies for Cancer

CRISPR/Cas9 Screening: Unraveling Cancer Immunotherapy's 'rosetta Stone'.

Use of CRISPR-based screens to identify mechanisms of chemotherapy resistance

CRISPR-based genetic screens advance cancer immunology

CRISPR-Cas and CRISPR-based screening system for precise gene editing and targeted cancer therapy

Unraveling Therapeutic Targets in Acute Myeloid Leukemia Through Multiplexed Genome Editing CRISPR Screening.

Applying CRISPR-Cas9 screens to dissect hematological malignancies

Exposing Cancer with CRISPR-Cas9: from Genetic Identification to Clinical Therapy

Tumor immunology CRISPR screening: present, past, and future

High-content CRISPR screening in tumor immunology

Developing Pioneering Pharmacological Strategies with CRISPR/Cas9 Library Screening to Overcome Cancer Drug Resistance

Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy

CRISPR/Cas9 high-throughput screening in cancer research

CRISPR-cas9: a powerful tool towards precision medicine in cancer treatment